John A. Scarlett's Insider Trades & SAST Disclosures
John A. Scarlett's most recent trade in Geron Corp. was a trade of 12,500 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on Feb. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John A. Scarlett.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.77 per share. | 27 Feb 2025 | 12,500 | 12,500 (0%) | 0% | 1.8 | 22,063 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 2,457,000 | 2,457,000 | - | - | Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 410,000 | 410,000 | - | - | Restricted Stock Units | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 1,000,000 | 1,000,000 | - | - | Employee Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.54 per share. | 04 Jun 2024 | 600,000 | 600,000 (0%) | 0% | 2.5 | 1,524,000 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2024 | 600,000 | 0 | - | - | Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 4.00 per share. | 04 Jun 2024 | 600,000 | 600,000 (0%) | 0% | 4 | 2,400,000 | Common Stock |
| Geron Corp. | Scarlett A. John | Director, CHAIRMAN, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 3,000,000 | 3,000,000 | - | - | Employee Stock Option (Right to Buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 1,750,000 | 1,750,000 | - | - | Employee Stock Option (Right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 08 Feb 2023 | 446,668 | 446,668 (0%) | 0% | 1.5 | 670,002 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 08 Feb 2023 | 446,668 | 0 (0%) | 0% | 3 | 1,340,004 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2023 | 446,668 | 0 | - | - | Employee Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 3.03 per share. | 08 Feb 2023 | 446,666 | 0 (0%) | 0% | 3.0 | 1,353,398 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 08 Feb 2023 | 446,666 | 446,666 (0%) | 0% | 1.5 | 669,999 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 3.08 per share. | 08 Feb 2023 | 446,666 | 0 (0%) | 0% | 3.1 | 1,375,731 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 08 Feb 2023 | 446,666 | 446,666 (0%) | 0% | 1.5 | 669,999 | Common Stock |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2023 | 446,666 | 0 | - | - | Employee Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2023 | 446,666 | 0 | - | - | Employee Stock Option (right to buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 2,100,000 | 2,100,000 | - | - | Employee Stock Option (Right to buy) | |
| CytomX Therapeutics Inc | John A. Scarlett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Geron Corp. | John A. Scarlett | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 600,000 | 600,000 | - | - | Employee Stock Option (Right to buy) | |
| CytomX Therapeutics Inc | John A. Scarlett | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges